Status:
RECRUITING
Mandibular Splint vs Botox Injection in Lateral Pterygoid on Cervical Muscle Activity in Patients With Temporomandibular Disorders
Lead Sponsor:
Cairo University
Conditions:
Mandibular Splint
Botox
Eligibility:
All Genders
18-40 years
Phase:
NA
Brief Summary
The study aims to compere mandibular splint versus botox injection in lateral pterygoid on cervical muscle activity in patients with temporomandibular disorders
Detailed Description
Temporomandibular disorders (TMD) are common chronic musculoskeletal pain conditions among orofacial pain, consisting of a group of conditions associated with pain and dysfunction of the temporomandib...
Eligibility Criteria
Inclusion
- Age from 18-40 years old.
- Both sexes.
- Duration of the disease is more than 3 months.
- Anterior mandibular disc displacement with reduction will be included.
- Unilateral anterior mandibular displacement with reduction grade 2\&3 (Wilkes) will be included.
- Patients with cervical muscles spasm and trigger points (upper trapezius\& sternocleidomastoid) will be included.
- Patients with sufficient cognitive abilities that enables them to understand and follow instructions.
Exclusion
- Neurological or musculoskeletal diseases that affect cervical spine other than mandibular disc displacement (eg: cervical spondylosis, spondylolisthesis, and cervical disc injuries)
- Bilateral anterior mandibular disc displacement patients.
- Musculoskeletal disorders such as severe arthritis, cervical spine surgery or contractures of fixed deformity, leg length discrepancy.
- women during pregnancy and lactation.
- Patients with known hypersensitivity to any component of the drug (especially hypersensitivity to human albumin).
- Patients with infection or inflammation of the area where the toxin injections are planned, in patients with musculoskeletal conduction disorders, in primary muscular disorders (muscular dystrophy, neuromyopathy, congenital myopathies, myotonic disorders, mitochondrial myopathy and unspecified or other primary muscle disorders).
- Patients being treated with aminoglycoside antibiotics, ciclosporin, D-penicillamine, tubocurarine, pancuronium, gallamine, succinylcholine, chloroquine, or hydroxychloroquine.
- History of cervical spine surgery.
- History of trauma or fractures in cervical spine.
- Signs of cervical radiculopathy or myelopathy.
- Vascular syndrome such as vertebrobasilar insufficiency.
- Signs of serious pathology ( e.g., malignancy, inflammatory disorders, infection).
Key Trial Info
Start Date :
August 14 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2025
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT06553950
Start Date
August 14 2024
End Date
February 1 2025
Last Update
August 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cairo University
Cairo, Egypt, 11796